Treatment Resistant Depression - Pipeline Insight, 2024

This “Treatment Resistant Depression - Pipeline Insight, 2024,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Treatment Resistant Depression Understanding

Treatment Resistant Depression: Overview

The term “treatment resistant depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), a2-antagonists, Agomelatine, Tianeptine are used for Treatment-Resistant Depression Treatment. Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant.

Treatment Resistant Depression - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Treatment Resistant Depression pipeline landscape is provided which includes the disease overview and Treatment Resistant Depression treatment guidelines. The assessment part of the report embraces, in depth Treatment Resistant Depression commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Treatment Resistant Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Treatment Resistant Depression R&D. The therapies under development are focused on novel approaches to treat/improve Treatment Resistant Depression.

Treatment Resistant Depression Emerging Drugs Chapters

This segment of the Treatment Resistant Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Treatment Resistant Depression Emerging Drugs

Psilocybin: COMPASS PathwaysPsilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.

AXS-05: Axsome TherapeuticsAXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor

Treatment Resistant Depression: Therapeutic Assessment

This segment of the report provides insights about the different Treatment Resistant Depression drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Treatment Resistant Depression

There are approx. 25+ key companies which are developing the therapies for Treatment Resistant Depression. The companies which have their Treatment Resistant Depression drug candidates in the most advanced stage, i.e. preregistration include, Axsome Therapeutics.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Treatment Resistant Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Treatment Resistant Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Treatment Resistant Depression drugs.

Treatment Resistant Depression Report Insights

• Treatment Resistant Depression Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Treatment Resistant Depression Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Treatment Resistant Depression drugs?
• How many Treatment Resistant Depression drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Treatment Resistant Depression?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Treatment Resistant Depression therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Treatment Resistant Depression and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Axsome Therapeutics
• COMPASS Pathways
• Merck Sharp & Dohme Corp.
• Navitor Pharmaceuticals, Inc.
• Taisho Pharmaceutical Co., Ltd.
• GH Research Limited
• Novartis Pharmaceuticals
• Reckitt Benckiser LLC
• Relmada Therapeutics, Inc.
• SAGE Therapeutics
• Navitor Pharmaceuticals
• Sumitomo Dainippon Pharma
• Alkermes
• AbbVie
• Janssen Pharmaceuticals
• Celon Pharma
• ACADIA Pharmaceuticals
• Pherin Pharmaceuticals
• ATAI Life Sciences

Key Products

• Psilocybin
• AXS-05
• MK-1942
• NV-5138
• TS-161
• GH 001
• MIJ821
• venlafaxine XR
• REL-1017
• SAGE-217
• NV-5138
• SEP-378614
• ALKS-5461
• Cariprazine
• Seltorexant
• Esketamine DPI
• Pimavanserin
• PH 10 nasal spray
• Arketamine

This product will be delivered within 2 business days.